Please assess the completion status of the following clinical trial:

Trial Title: Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary epithelial OC patients with measurable tumor lesions (determined by CT or MRI), who are intended to be treated with neo-adjuvant chemotherapy (carboplatin/paclitaxel), subsequent surgery and adjuvant chemotherapy~* Age ≥ 18 years~* Signed informed consent in accordance with institutional and regulatory guidelines~* Adequate access of the tumor for image-guided biopsy~* Adequate (according to the institutional standards) hematology, liver and kidney function to undergo chemotherapy with carboplatin and paclitaxel~* ECOG-performance status of 0 or 1 at screening~* Current BMI \> 18.5 and no weight loss of \>5% over the past month. Notably, weight loss due to drainage of ascites is not applicable.~Exclusion Criteria:~* History of a second malignancy except for curatively treated low-stage tumors with a histology that can be differentiated from the epithelial OC type~* History of an autoimmune disease, specifically HAV, HBV, HCV and HIV, or any other systemic intercurrent disease or condition that might affect the immunocompetence of the patient, or treatment with systemic highly immunosuppressive therapy (e.g. transplant recipients or patients who underwent a splenectomy)~* Use of systemic continuous corticosteroid therapy (e.g. prednisone i.v. or p.o. \>7.5 mg / day).~* Pregnancy or breast feeding~* Participation in a trial with another investigational drug within 30 days prior to the enrolment in this trial~* Any condition that in the opinion of the investigator could interfere with the conduct of the trial.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): Patients will receive 8 W_ova1 vaccinations before and during neoadjuvant chemotherapy and adjuvant chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).